B I09 NEW
| Price | $44 | $98 | $163 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-06-02 |
Product Details
| Product Name: B I09 | CAS No.: 1607803-67-7 |
| Purity: 99.64% | Supply Ability: 10g |
| Release date: 2026/06/02 |
Product Introduction
Bioactivity
| Name | B I09 |
| Description | B I09, an IRE-1 RNase inhibitor with an IC50 of 1230 nM, inhibits splicing of XBP1 mRNA in human WaC3 cells and expression of xbp-1 in LPS-stimulated B cells. B I09 can be used to simulate the defects of XBP-1 in CLL cells., an IRE-1 RNase inhibitor with an IC50 of 1230 nM, inhibits splicing of XBP1 mRNA in human WaC3 cells and expression of xbp-1 in LPS-stimulated B cells. B I09 can be used to simulate the defects of XBP-1 in CLL cells., an IRE-1 RNase inhibitor with an IC50 of 1230 nM, inhibits splicing of XBP1 mRNA in human WaC3 cells and expression of xbp-1 in LPS-stimulated B cells. B I09 can be used to simulate the defects of XBP-1 in CLL cells. |
| In vitro | B I09 is an IRE-1 RNase inhibitor with an IC50 of 1230 nM[1], effectively inhibiting the splicing of XBP1 mRNA in human WaC3 cells and the expression of XBP-1s in LPS-stimulated B cells[2]. Treatment of CLL cells with B I09 mimics XBP-1 deficiency, including upregulation of IRE-1 expression and compromised BCR signaling. |
| In vivo | B I09 exhibits a half-life of roughly 1.5 hours and achieves its maximum concentration of about 39 μM in mouse plasma serum within 15 minutes post-administration. Upon administration to mice bearing CLL tumors, B I09 effectively halts leukemic progression through apoptosis induction, without inducing systemic toxicity[2]. |
| Storage | Powder: -20°C for 3 years Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 3.75 mg/mL (12.36 mM), Solution. 10% DMSO+90% Saline : < 3.75 mg/mL (12.36 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. DMSO : 37.5 mg/mL (123.64 mM), Sonication is recommended. |
| Keywords | IRE-1 RNase | IRE1 Rnase | B I-09 | B I09 |
| Inhibitors Related | Sunitinib | 6-Bromo-2-hydroxy-3-methoxybenzaldehyde | Sunitinib Malate | D-F07 | STF-083010 | Z4P | MKC8866 | APY29 | GSK2850163 (S enantiomer) | KIRA6 | GSK2850163 | Toyocamycin |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
VIP6Y
|
RongNa Biotechnology Co.,Ltd
|
2026-06-24 | ||
| $35.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-06-02 | |
|
VIP2Y
|
Xi an Biohorlden Industry Trade Co Ltd
|
2026-06-24 | ||
| $44.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-06-02 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY